Solstein Capital’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,036
Closed -$131K – 249
2026
Q2
$131K Hold
1,036
– – 0.04% 161
2026
Q1
$144K Hold
1,036
– – 0.06% 146
2025
Q4
$127K Hold
1,036
– – 0.05% 149
2025
Q3
$115K Hold
1,036
– – 0.03% 150
2025
Q2
$115K Hold
1,036
– – 0.06% 144
2025
Q1
$116K Hold
1,036
– – 0.07% 123
2024
Q4
$95.7K Hold
1,036
– – 0.05% 131
2024
Q3
$86.9K Hold
1,036
– – 0.05% 137
2024
Q2
$71.1K Hold
1,036
– – 0.05% 135
2024
Q1
$75.9K Hold
1,036
– – 0.05% 125
2023
Q4
$83.9K Hold
1,036
– – 0.06% 126
2023
Q3
$77.6K Hold
1,036
– – 0.07% 128
2023
Q2
$79.8K Hold
1,036
– – 0.07% 129
2023
Q1
$86K Hold
1,036
– – 0.07% 123
2022
Q4
$88.9K Hold
1,036
– – 0.07% 134
2022
Q3
$64K Hold
1,036
– – 0.06% 142
2022
Q2
$64K Hold
1,036
– – 0.05% 162
2022
Q1
$62K Hold
1,036
– – 0.04% 178
2021
Q4
$75K Hold
1,036
– – 0.05% 183
2021
Q3
$72K Hold
1,036
– – 0.04% 204
2021
Q2
$71K Hold
1,036
– – 0.09% 194
2021
Q1
$67K Buy
+1,036
New +$66.8K 0.09% 189
2020
Q4
– Sell
-1,036
Closed -$65K – 136
2020
Q3
$65K Hold
1,036
– – 0.15% 117
2020
Q2
$80K Hold
1,036
– – 0.19% 90
2020
Q1
$77K Buy
1,036
+480
+86% +$33.2K 0.3% 57
2019
Q4
$36K Buy
+556
New +$36.2K 0.07% 128

Other funds holding GILD

Solstein Capital's GILD Position: Q3 2026 in Review

Solstein Capital sold out of Gilead Sciences (GILD) in Q3 2026, closing a stake of 1,036 shares — an estimated $131K sold.

Solstein Capital first reported a position in GILD in Q4 2019 and held it in 26 quarters. The position peaked at $144K in Q1 2026. 2,328 funds tracked by Wall St. Rank hold GILD as of Q3 2026.

  • Solstein Capital reported no remaining Gilead Sciences position as of Q3 2026 after selling out during the quarter.
  • Solstein Capital sold 1,036 Gilead Sciences shares in Q3 2026, an estimated $131K.
  • Solstein Capital first reported a position in Gilead Sciences in Q4 2019 and held it in 26 quarters.
  • Solstein Capital's Gilead Sciences position peaked at $144K in Q1 2026.
  • 2,328 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.

Based on Solstein Capital's 13F filing for Q3 2026, filed 2 Nov 2026.